

<b>Reference:</b>	FOI.19269.26
<b>Subject:</b>	Intra-vitreous injections or implants
<b>Date of Request:</b>	9 January 2026

**Requested:**

- How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from September to December 2025:
  - Aflibercept
  - Bevacizumab
  - Brolucizumab
  - Dexamethasone
  - Faricimab
  - Fluocinolone acetonide
  - Ranibizumab - Lucentis
  - Ranibizumab - Biosimilar
- Please provide the number of injections/implants administered by eye condition for the four-month period from September to December 2025:

Number of Injections/Implants: September to December 2025:

Treatment	Eye Conditions			
	Wet Age-Related Macular Degeneration (wAMD)	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)	Non-infectious Uveitis (NIU)
Aflibercept				
Bevacizumab				
Dexamethasone				
Faricimab				
Fluocinolone aceronide				
Ranibizumab - Lucentis				
Ranibizumab - Biosimilar				

**Response:**

- Hywel Dda University Health Board (UHB) provides within the table below, the number of each of the listed intravitreal injections/implants administered, during the period 1 September to 31 December 2025.

Medication	Number
Aflibercept	583
Bevacizumab	0
Brolucizumab	0
Dexamethasone	116
Faricimab	1,540
Fluocinolone acetonide	2
Ranibizumab - Lucentis	21
Ranibizumab - Biosimilar	1,276

2. The UHB provides within the table below, the number of each of the listed intravitreal injections/implants administered, by eye condition, during the period September to 31 December 2025.

Treatment	Eye Conditions			
	Wet Age-Related Macular Degeneration (wAMD)	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)	Non-infectious Uveitis (NIU)
Aflibercept	313	149	121	0
Bevacizumab	0	0	0	0
Dexamethasone	0	54	59	3
Faricimab	1,061	238	241	0
Fluocinolone acetonide	0	1	1	0
Ranibizumab - Lucentis	15	3	3	0
Ranibizumab - Biosimilar	799	188	289	0